This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Urinary Cytokine Levels as a Prognostic Marker for Kidney Scarring After Pyelonephritis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2009 by Hillel Yaffe Medical Center.
Recruitment status was:  Not yet recruiting
Sponsor:
Information provided by:
Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier:
NCT00868270
First received: March 22, 2009
Last updated: NA
Last verified: March 2009
History: No changes posted
  Purpose
The prevalence of kidney scarring after UTI is approximately 5-57%. UTIs are caused mainly by bacteria that cause local and systemic immunological reaction that are accompanied by cytokines. These cytokines are a main factor in the inflammatory process. They are produced by leukocytes, macrophages, fibroblasts, endothelial cells and epithelial cells in the kidney tissue. Interleukin 6 and 8 (IL-6 IL-8) were found in high levels in the urine of children and adults who suffer from UTIs. Other studies on animals have found a relationship between inflammatory reaction and scarring in the kidney. We hypothesize that we will find a similar relationship between the level of IL-6, IL-8 in the urine during acute pyelonephritis in children and the probability of kidney scarring.

Condition
Kidney Scarring Post-Febrile UTI

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Hillel Yaffe Medical Center:

Primary Outcome Measures:
  • High prevalence of kidney scarring in children with high levels of urine interleukins [ Time Frame: six months ]

Estimated Enrollment: 35
Study Start Date: May 2009
Groups/Cohorts
Children with UTIs

  Eligibility

Ages Eligible for Study:   up to 7 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Hospitalized children with UTIs
Criteria

Inclusion Criteria:

  • Children aged 0-7
  • First episode febrile UTI

Exclusion Criteria:

  • Recurrent UTI
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00868270

Contacts
Contact: Hassan Jassar, MD 972-4-630-4332 hasjassar@hotmail.com

Locations
Israel
Hillel Yaffe Medical Center Not yet recruiting
Hadera, Israel, 38100
Contact: Hassan Jassar, MD         
Sponsors and Collaborators
Hillel Yaffe Medical Center
  More Information

Responsible Party: Hassan Jassar, MD, Pediatrics Dept. Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier: NCT00868270     History of Changes
Other Study ID Numbers: HY55-08
Study First Received: March 22, 2009
Last Updated: March 22, 2009

Additional relevant MeSH terms:
Cicatrix
Fibrosis
Pathologic Processes

ClinicalTrials.gov processed this record on June 23, 2017